Glyceraldehyde-3-Phosphate Dehydrogenase

Catalog#	Product Description	Host Species	Nature	Cross reactivity	Quantity	Volume	Price
GPDH-101AP	GPDH antibodies	Rabbit	AP	h, others n.d.	100.0 ug	150-500 ul	$245.00
FITC-GPDH	FITC-conjugated antibodies	Rabbit	FITC-AP	h, others n.d.	100.0 ug	150-500 ul	$350.00
P-GPDH	Antigenic blocking peptide	n/a	Synthetic peptide	n/a	250.0 ug	100 ul	$125.00
PC-GPDH	WB positive control for GPDH	n/a	Protein in ready-to-use buffer	n/a	0.0 ug	150 ul	$185.00

Glyceraldehyde-3-phosphate dehydrogenase (GPDH) is a glycocytic enzyme which catalyzes the reversible oxidative phosphorylation of glyceraldehyde-3-phosphate in the presence of inorganic phosphate and nicotinamide adenine dinucleotide (NAD) (1). This enzyme exists as a tetramer of identical chains. It is found on a cell’s membrane, in the cytoplasm and in the nucleus, therefore, it has been shown to display several different activities. It functions in endocytosis, microtubule bundling, phosphotransfer activity, nuclear tRNA export, DNA replication and DNA repair (2). Recently, GPDH has been shown to play a significant role in the development of diabetic retinopathy and its progression after cessation of hyperglycemia (3). GPDH is also known as an initiation signal for cellular apoptosis or programmed cell death (PCD). Since PCD has shown to play some role in both chronic and acute human neurodegenerative disorders, GAPDH may serve as a target for anti-apoptotic compounds with the potential to slow or prevent the progression of neurodegenerative disorders (4).

PCD was shown to be initiated after the small scale translocation of GPDH in the nucleus that acts as a transcription factor for the synthesis of new GPDH protein. This protein is targeted for nucleus and has the characteristics of a novel isozyme that acts as a transcription factor for pro-apoptotic signals (5). Therefore, increase in nuclear GPDH is associated with susceptible neurons in postmortem samples from patients with a variety of neurodegenerative conditions. Small-molecule compounds that selectively bind GAPDH prevent the increase in GPDH synthesis and nuclear accumulation, hence preventing the cells from undergoing apoptosis (6). Such compounds are being considered as disease-modifying agents for neurodegenerative diseases. GPDH is approximately a 39kDa protein (333 amino acids).

The GPDH-selective antibodies were generated against purified glyceraldehydes-3-phosphate dehydrogenase (GPDH) protein. GPDH -antibodies are affinity purified over immobilized antigen based chromatography, and the purified immunoglobulins are stabilized in antibody stabilization buffer. FabGennix Int. Inc., will also provide limited quantities of antigenic blocking protein for GAPDH -101AP antibody. Antibodies to GPDH (GPDH -101AP) will label ~39kDa protein in Western blot positive control samples for GAPDH and several other tissues. FabGennix Inc. will also conjugate antibodies with secondary enzymes (alk-Pase or HRP) or fluorescent probes upon request at nominal cost.

For research use only, not for diagnostic or therapeutic use.

Data Sheets
Glyceraldehyde-3-Phosphate Dehydrogenase

MSDS

Related Items

General Information

Citations
Search FabGennix Product Citation Data Base
Search